Polycystic ovary syndrome and valproic acid;Síndrome de ovario poliquístico y ácido valproico

Revista de Neurologia

Volumn 37, Issue 10, 2003, Pages 975-982

  Ribacoba Montero, R ^a,c   Martinez Faedo C ^b   Salas Puig, J ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Hospital Alvarez Buylla   (Spain)

^c HOSPITAL ÁLVAREZ BUYLLA   (Spain)

Author keywords

Antiepileptic drugs (AED); Epileptic females; Polycystic ovary syndrome (POS); Valproic acid (VPA)

Indexed keywords

VALPROIC ACID;

DISEASE ASSOCIATION; EPILEPSY; FEMALE; HUMAN; MEDICAL RECORD; MENSTRUAL CYCLE; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; REVIEW; SPONTANEOUS ABORTION; VIRILIZATION;

EID: 0345168862     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3710.2002615     Document Type: Review

References (64)

1. Isojärvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383-8.
2. Popovic V, Spremovic S. The effect of sodium valproate on lutheinizing hormone secretion in women with polycystic ovary disease. J Endocrinol Invest 1995; 18: 104-8.
3. Isojärvi JIT, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries. Arch Neurol 2000; 57: 1064-8.
4. Herzog AG, Schachter SC. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia 2001; 42: 311-5.
5. Luef G, Abraham I, Trinka E, Alge A, Windisch J, Daxenbichler G, et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002; 48: 91-102.
6. Herzog AG. Polycystic ovarian syndrome in women with epilepsy. Epileptic or iatrogenic? Ann Neurol 1996; 39: 559-60.
7. Bauer J, Jarre A, Klingmüller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41: 163-7.
8. Murialdo G, Galimberti CA, Gianelli MV. Menstrual cycle and ovary alteration in women with epilepsy on antiepileptic drugs. J Endocrinol Invest 1997; 20: 519-26.
9. Joffe H, Taylor AE, Hall JE. Polycystic ovarian syndrome. Relationship to epilepsy and antiepileptic drug therapy. J Clin. Endocrinol Metab 2001; 86: 2946-9.
10. Betts T, Dutton N, Yarrow H. Epilepsy and the ovary (cutting out the hysteria). Seizure 2001; 10: 220-8.
11. Nappi C, Meo R, Di Carlo C, Estranco A, Bilo I. Reduced fertility and endocrine dysfunction in women with epilepsy. Gynecol Endocrinol 1994; 8: 133-45.
12. Morrell MJ. Effects of epilepsy on women's reproductive health. Epilepsia 1998; 39 (Suppl 8): S32-7.
13. Tettenborn B, Genton P, Polson D. Epilepsy and women's issues: an update. Epileptic Disord 2002; 4 (Suppl 2): S23-31.
14. Herzog AG. A relationship between particular reproductive endocrine disorders and epileptiform discharges in women with epilepsy. Neurology 1993; 43: 1907-10.
15. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999; 53 (Suppl 1): S42-8.
16. Bilo L, Meo R, Valentino R, Di Carlo C, Striano S, Nappi C. Characterization of reproductive endocrine disorders in woman with epilepsy. J Clin Endocrinol Metab 2001; 86: 2950-6.
17. Morrell MJ, Giudice L, Flymn KL, Seale CG, Paulson AJ, Doñe S, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002; 52: 704-11.
18. Bauer J, Isojärvi JIT, Herzog AG, Polson D, Taubell E, Genton P, et al. Reproductive dysfunction in woman with epilepsy recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 2002; 73:121-5.
19. Balasch J. Síndrome de los ovarios poliquísticos: de la ginecología a la endocrinología o hacia una concepción unitaria. Endocrinología 1999; 46: 251-2.
20. Duncan S. Polycystic ovarian syndrome in woman with epilepsy: a review. Epilepsia 2001; 42 (Suppl 3): 60-5.
21. Hopkinson J, Sattar N, Fleming R, Greer IA. Polycystic ovarian syndrome: the metabolic syndrome come to gynaecology. BMJ 1998; 317: 329-32.
22. Dueñas-Díez JL, Cano-Sánchez A, Castelo-Branco C, Espinós-Gómez JJ, Marín-García JM, Neyro-Bilbao JL, et al (Grupo síndromes hiperandrogénicos). Síndromes hiperandrogénicos. Cabero-Raura LL, Junta Directiva de la Sociedad Española de Ginecología y Obstetricia, eds. Documentos de consenso SGEO. Madrid: Meditex; 1998. p. 110-42.
23. Fatterweit W. Polycystic ovary syndrome: clinical perspectives and management. Obstet Gynecol Survey 2000; 54: 403-15.
24. Isojärvi JIT, Taubell E, Pakarinen AJ, van Parys J, Rättyä J, Harbo HF, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001; 111: 290-6.
25. Zawadsky JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome (toward a rational approach. In Dunaif A, Givero JR, Haseltine FP, Merriam GR, eds. Polycystic ovary syndrome. Oxford: Blackwell Scientific; 1992. p. 377-84.
26. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 854-61.
27. Knochenhauser ES, Key TJ, Kahsar-Miller M. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-82.
28. Creswell JL, Barker DJP, Osmond C, Egger P, Phillips DIW, Fraser RB. Fetal growth length of gestation and polycystic ovaries in adult life. Lancet 1997; 350: 1131-5.
29. Balen A. Pathogenesis of polycistic ovary syndrome -the enigma unravels? Lancet 1999; 354: 966-7.
30. Adams J, Franks S, Polson DW. Multi-follicular ovaries: clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone. Lancet 1985; 2: 1375-8.
31. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998; 27: 877-901.
32. Poretsky L, Cataldo N, Rosenwaks Z, Giudice L. The insulin related ovarian regulatory system in health and disease. Endocr Rev 2000; 20: 535-82.
33. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999; 28: 361-78.
34. Sozen H, Arici A. Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome. Obstet Gynecol Survey 2000; 55: 321-8.
35. Dunaif A. Hyperandrogenic anovulation (POCS): a unique disorder of insulin action associated with increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98 (Suppl 1A): S33-9.
36. Dunaif A. Insulin action in the polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28: 341-59.
37. Wu X, Sallimen K, Antila L, Makinen M, Luo C, Pollamen P, et al. Expression of insulin-receptor substrate-1 and -2 in ovaries from women with insulin resistance and from controls. Fertil Steril 2000; 74: 564-72.
38. Warrel BC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003; 28: 126-9.
39. Isojärvi J, Laatikainer TJ, Knip M, Pakarinen AJ, Kaisa TS, Juntunen K, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996; 39: 579-84.
40. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 56: 172-7.
41. Genton P, Bauer J, Duncan S, Taylor AE, Balen AH, Eberle A, et al. On the association between valproate and polycistic ovary syndrome. Epilepsia 2001; 42: 295-304.
42. Luef G, Abraham I, Trinka E, Unterberger I, Hoppichler F, Bauer G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001; 57: 565-6.
43. Luef G, Abraham I, Haslinger M. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002; 249: 835-41.
44. Morrell MJ. Seizures and epilepsy in women. In Kaplan PW, ed. Neurologic disease in women. New York: Demos Medical Publishing; 1998. p. 189-206.
45. El Sayed-Yaser Y. Obstetric and gynecologic cure of woman in epilepsy. Epilepsia 1998; 39 (Suppl 8): 517-25.
46. Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. The women of epilepsy guidelines development group. Best practice guidelines for the management of women with epilepsy. Seizure 1999; 8: 201-17.
47. Herzog A, Seibel M, Schomer DL, Vaitukaitis JL, Geswind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43: 341-6.
48. Herzog A, Seibel M, Schomer DL, Vaitukaitis JL, Geswind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology 1984; 34: 1389-93.
49. Bilo L, Meo R, Nappi C. Reproductive endocrine disorder in women with primary generalized epilepsy. Epilepsia 1988; 29: 612-9.
50. Cummings LN, Giudice L, Morrel MJ. Ovulatory function in epilepsy. Epilepsia 1995; 36: 355-9.
51. Drislane FW, Coleman AE, Schomer DL, Ives J, Levesque LA, Seibel MM, et al. Altered pulsatile secretion of luteinizing hormone in women with epilepsy. Neurology 1994; 44: 306-10.
52. Schomer DL. Ovarian hormones and the nervous system. In Kaplan PW, ed. Neurologic disease in women. New York: Demos Medical Publishing; 1998. p. 45-51.
53. Bilo L, Meo R, Valentino R. Abnormal pattern of luteinizing hormone pulsatily in women with epilepsy. Fertil Steril 1991; 55: 705-11.
54. Benstall GH, Cowan RA, Gray JMB, Fogelman I. Hormone binding globulins and anticonvulsivants therapy. Scott Med J 1985; 30: 101-5.
55. Stoffel-Wagner B, Bauer J, Flugel D, Brememan W, Klingmuller D, Elger CE. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia 1998; 39: 1164-73.
56. Franceschi M, Perego L, Cavagnini F. Effect of long-term antiepileptic therapy on the hypothalamic-pituitary axis in man. Epilepsia 1984; 25: 46-52.
57. Vainionpää L, Rättyä J, Knip M, Tapanainen JS, Pakarinen A, Lanning P, et al. Valproate induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999; 45: 444-50.
58. Rättyä J, Vainionpää L, Knip M, Lanning P, Isojärvi J. The effects of valproate, carbamazepine and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103: 388-93.
59. O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322-30.
60. Murialdo G, Galimberti CA, Gianlelli MV, Rollero A, Polleri A, Copeelo F, et al. Effects of valproate, phenobarbital and carbamazepine on sex steroid setup in women with epilepsy. J Clin Neuropharmacol 1998; 20: 52-8.
61. Rättya J, Pakarinen AJ, Knip M, Repo-Outakoski M, Myllylá VV, Isojärvi JIT. Early hormonal changes during valproate or carbamazepine treatment. A 3-month study. Neurology 2001; 57: 440-4.
62. Tauboll E, Isojarvy JI, Harbo HF, Pakarnen AJ, Gjerstad L. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure 1999; 8: 490-3.
63. Ferin M, Morrell M, Xiao E, Kochan L, Qian F, Wright T, et al. Endocrine and metabolic response to long-term monotherapy with the antiepileptic drug valproate in the normally cycling rhesus monkey. J Clin Endocrinol Metab 2003; 88: 2908-15.
64. Reuber M, Goulding PJ. Valproate, polycistic ovary syndrome and the need for a prospective study. Seizure 2000; 9: 235-6.